An analytical framework for assessing drug and therapeutics committee structure and work processes in tertiary Brazilian hospitals

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 3, 2014, Pages 268-276

  da Costa Lima Dellamora, Elisangela ^a,b   Caetano, Rosângela ^c   Gustafsson, Lars L ^d   Godman, Brian B ^b,d,e   Patterson, Ken ^f   Osorio de Castro, Claudia Garcia Serpa ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAZIL; DRUG SCREENING; FACTUAL DATABASE; LEGISLATION AND JURISPRUDENCE; ORGANIZATION AND MANAGEMENT; PHARMACY AND THERAPEUTICS COMMITTEE; PROCEDURES; TEACHING HOSPITAL;

BRAZIL; DATABASES, FACTUAL; DRUG EVALUATION; HOSPITALS, TEACHING; PHARMACY AND THERAPEUTICS COMMITTEE;

EID: 84906080889     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12215     Document Type: Article

References (69)

1. Malmström RE, Godman B, Diogene E, Asola E, Baumgärtel C, Bennie M et al. Dabigatran - a case history demonstrating the need for comprehensive models to optimise the entry of new drugs in Europe. Front Pharmacol 2013;4:1-31.
2. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov 2011;10:495-506.
3. Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, Hasselström J et al. The 'Wise List'- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108:224-33.
4. Godman B, Paterson K, Malmstrom R, Selke G, Fagot JP, Mrak J. Improving the managed entry of new medicines: sharing experiences across Europe. Exp Rev Pharmacoeconom Outcomes Res 2012;12:439-41.
5. Vianna CMM, Caetano R. Economic analyses as a tool in the process of health technology incorporation. Cad Saúde Colet 2005;13:747-66.
6. Prescrire Editorial Staff. New drugs and indications in 2010: inadequate assessment; patients at risk. Rev Prescrire 2001;31:134-41.
7. Davis C, Abraham J. The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US. Soc Sci Med 2011;72:1574-81.
8. Anderson G, Steingerg E, Heyssel R. The pivotal role of the academic health center. Health Aff 1994;13:146-58.
9. Björkhem-Bergman J, Andersen-Karlsson E, Laing R, Diogene E, Melien M, Jirlow M et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013;69:73-8.
10. Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. Br Med J 2001;323:378-81.
11. Trindade EA. Adoption of new technologies by health services: the challenge of analyzing relevant factors. Rep Pub Health 2008;24:951-64.
12. Brazil. Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatística). http://www.ibge.gov.br/home/ (last accessed on 4 August 2013).
13. Paim J, Travassos C, Almeida C, Bahia L, Macinko J. The Brazilian health system: history, advances, and challenges. Lancet 2011;377:1778-97.
14. O'Dwyer GO, Oliveira SP, Seta MH. Evaluation of emergency services of the hospitals from the QualiSUS program. Ciênc Saúde Colet 2009;14:1881-90.
15. Medici AC. University hospitals: past, present and future. J Brazilian Med Assoc 2001;47:149-56.
16. Lima-Dellamora. Adoption of new drugs in university hospitals in Rio de Janeiro. (Incorporação de medicamentos novos em hospitais universitários do estado do Rio de Janeiro) PhD thesis. Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, 2012.
17. Lima EC, Sandes VS, Caetano R, Osorio-de-Castro CGS. Incorporation and usage of financially relevant medicines in a tertiary federal university hospital. Cad Saúde Colet 2010;18:551-9.
18. Aurea AP, Magalhães LCG, Garcia LP, Santos CF, Almeida RF. Federal Government's Assistance Pharmaceutical Programs: Structure, Expenditures With Drugs and First Evidences of Efficiency, 2005-2008 (Programas de Assistência Farmacêutica do Governo Federal: Estrutura Atual, Evolução dos Gastos com Medicamentos e Primeiras Evidências de sua Eficiência, 2005-2008). Applied Economic Research Institute (Instituto de Pesquisa Econômica Aplicada), Brasília, 2011.
19. Pan American Health Organization. Access to High-Cost Medicines in the Americas: Situation, Challenges and Perspectives. PAHO, Washington, DC, 2010.
20. Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L et al. Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 2010;107:531-59.
21. Godman B, Wettermark B, Hoffman M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Exp Rev Pharmacoecon Outcomes Res 2009;9:65-83.
22. Hoffmann M. The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees. Eur J Clin Pharmacol 2013;69:79-87.
23. Prosser H, Walley T. New drug prescribing by hospital doctors: the nature and meaning of knowledge. Soc Sci Med 2006;62:1565-78.
24. World Health Organization. Selection of essential medicines. Policy Pers Med WHO 2002;4:1-6.
25. Machado SP, Kuchenbecker R. University hospitals in Brazil: challenges and future perspectives. Ciênc Saúde Colet 2007;12:871-7.
26. Barbosa PR. Inovation in health services: methodological and analytical dimensions regarding innovation dynamics in hospitals (Inovações em serviços de saúde: dimensões analíticas e metodológicas na dinâmica de inovação em hospitais). PhD thesis. Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, 2009.
27. Marques DC, Zucci P. Pharmacy and therapeutics committees in Brazil: lagging behind international standarts. Pan Am J Pub Health 2006;19:58-63.
28. Osorio-de-Castro CGS, Castilho SR. Results: Phase 1. In: National Assessment of Brazilian Hospital Pharmacies (Diagnóstico da Farmácia Hospitalar no Brasil). Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, 2004;27-35.
29. World Health Organization. Drug and Therapeutics Committees: A Practical Guide Department of Essential Drugs and Medicines Policy. WHO, Geneva, 2003.
30. Brazil. National Registry of Health Facilities. http://www.cnes.datasus.gov.br (last accessed on 15 September 2013).
31. Porto Alegre General Hospital (PAGH). Medicines Committee (Comissão de Medicamentos - Comedi). http://www.hcpa.ufrgs.br/content/view/1008/975/ (last accessed on 12 May 2013).
32. Mannebach MA, Ascione FJ, Gaither CA, Bagozzi RP, Cohen IA, Ryan ML. Activities, functions, and structure of pharmacy and therapeutics committees in large teaching hospitals. Am J Health-Syst Pharm 1999;56:622-8.
33. Thuèrmann PA, Harder AS, Steioff AA. Structure and activities of hospital drug committees in Germany. Eur J Clin Pharmacol 1997;52:429-35.
34. Fijn R, Brouwers RBJ, Knaap RJ, De Jong-Van den Berg LTW. Therapeutics Committees in Dutch hospitals: a nation-wide survey of structure, activities, and drug selection procedures. J Clin Pharmacol 1999;48, 239-46.
35. Wirtz W, Cribb A, Barber N. Reimbursement decisions in health policy-extending our understanding of the elements of decision-making. Health Policy 2005;73:330-8.
36. Booth-Clibborn N, Packer C, Stevens A. Health technology diffusion rates in England. Int J Technol Assess Health Care 2000;16:781-6.
37. Chauhan D, Mason A. Factors affecting the uptake of new medicines in secondary care - a literature review. J Clin Pharm Ther 2008;33:339-48.
38. Weekes LM, Day RO. The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees: an Australian perspective. Drug Saf 1998;18:153-9.
39. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-80.
40. Gertner A. Science of uncertainty: making cases for drug incorporation in Brazil. Anthropol Quart 2010;83:97-122.
41. Messeder AM, Osorio-de-Castro CGS, Luiza VL. Can court injunctions guarantee access to medicines in the public sector? The experience in the State of Rio de Janeiro, Brazil. Rep Pub Health 2005;21:525-34.
42. Hatton RC, Doering PL. Organization and operation of P & T Committees in the state of Florida: a survey. Hosp Formul 1990;25:983-9.
43. Odedina FT, Sullivan J, Nash R, Clemmons CD. Use of pharmacoeconomic data in making hospital formulary decisions. Am J Health-Syst Pharm 2002;59:1441-4.
44. Bagozzi RP, Ascione FJ, Mannebach MA. Inter-role Relationships in Hospital-based Pharmacy and Therapeutics Committee Decision Making. J Health Psychol 2005;10:45-64.
45. Tan LE, Day RO, Joanne E. Prioritising drug and therapeutics committee (DTC) decisions: a national survey. Pharm World Sci 2007;29:90-96.
46. Sjöqvist F, Bergman U, Dahl ML, Gustafsson LL, Hensjö LO. Drug and therapeutics committees: a Swedish experience. WHO Drug Inf 2002;16:207-13.
47. Mittmann N, Knowles S. A survey of pharmacy and therapeutic committees across Canada: scope and responsibilities. Can J Clin Pharmacol 2009;16:171-7.
48. Vang C, Tomson G, Kounnavong S, Southammavong T, Phanyanouvong A, Johansson R et al. Improving the performance of Drug and Therapeutics Committees - a quasi-experimental study in Laos. Eur J Clin Pharmacol 2006;62:57-63.
49. Suh D, Okpara IR, Agnese WB, Toscani M. Application of pharmacoeconomics to formulary decision making in managed care organizations. Am J Manag Care 2002, 8:161-9.
50. Dranove D, Hughes EFX, Shanley M. Determinants of HMO Formulary Adoption Decisions. Health Serv Res 2003;38:169-90.
51. Tan LE, Day RO, Joanne E. Perspectives on Drug and Therapeutics Committee policy implementation. Res Social Adm Pharm 2005;1:526-45.
52. Farmer BM, Nelson LS. Conflicts of interest on Pharmacy and Therapeutics Committees at academic medical centers. J Med Toxicol 2011;7:175-6.
53. Stichele RV. The 'Wise List' - A comprehensive model for Drug and Therapeutics Committees to achieve adherence to recommendations for essential drugs among prescribers? Basic Clin Pharmacol Toxicol 2011;108:221-3.
54. Shankar PR, Humagain B, Piryani RM, Jha N, Osti B. Establishing and strengthening a medicine and therapeutics committee in a medical college in Nepal: initial experiences. Pharm World Sci 2009;31:241-5.
55. Palacios M, Rego S, Lino MH. Promotion and marketing strategy of medicines in teaching hospitals: elements for discussion (Promoção e propaganda de medicamentos em ambientes de ensino: elementos para o debate). Interface - Comum, Saúde, Educ. 2008;12:893-905.
56. Fagundes MJD, Soares MGA, Diniz NM, Pires JR, Garrafa V. Bioethical analysis of drugs advertisement and publicity. Ciênc Saúde Colet 2007;12:221-9.
57. Tan LE, Day RO, Joanne E. Drug and therapeutics committees - are they fulfilling their potential to improve the quality use of medicines? Int J Pharm Pract 2003;11:175-81.
58. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Exp Rev Pharmacoecon Outcomes Res 2012;12:125-30.
59. Anell A, Svarvar P. Pharmacoeconomics and clinical practice guidelines: a survey of attitudes in swedish formulary committees. Pharmacoeconomics 2000;17:175-85.
60. Fischer MA, Avorn J. Academic detailing can play a key role in assessing and implementing comparative effectiveness research findings. Health Aff 2012;31:2206-12.
61. Campos GWS. Physician training, university hospitals, and the unified health system in Brazil. Rep Pub Health 1999;15:187-93.
62. Schechter CB. Decision analysis in formulary decision making. Pharmacoeconomics 1993;3:454-61.
63. Sloan FA, Whetten-Goldstein K, Wilson A. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis. Soc Sci Med 1997;45:523-33.
64. Malone DC. The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines. J Manag Care Pharm 2005;11:7-10.
65. Martínez-Bengoechea MAJ, Viniegra A, Rozas SC, Arana A, Ibarra O, García MG. Selection criteria for inclusion of medicines in pharmacotherapeutic guideline (Criterios de seleccion de medicamentos para su inclusion en una guia farmacoterapeutica:eleccion y ponderacion). Farm Hosp 1996;20:60-6.
66. Anell A. Priority setting for pharmaceuticals: the use of health economic evidence by reimbursement and clinical guidance committees. Eur J Health Econom 2004;5:28-35.
67. Alfaro-Lara ER, Galván-Banqueri M, Prado-Mel E, Santos-Ramos B, Varela-Aguilar JM, Torelló-Iserte J et al. Analysis of the selection process for new drugs in a tertiary hospital 2004-2007. Farm Hosp 2010;34:76-84.
68. Plet HT, Hallas J, Nielsen GS, Kjeldsen LJ. Drug and therapeutics committees in danish hospitals: a survey of organization, activities and drug selection procedures. Basic Clin Pharmacol Toxicol 2013;112:264-9.
69. Weekes LM, Brooks C, Day RO. Indicators for drug and therapeutics committees. Br J Clin Pharmacol 1998;45:393-398.